Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
The purpose of this phase I/II trial is to evaluate the safety and efficacy of gadolinium-based nanoparticle, Activation, and Guidance of Irradiation X (AGuIX), used in combination with MR-guided stereotactic body radiation therapy (SBRT) in patients with lung tumors and pancreatic cancer.
Study ID: 19-826
Trial Phase: Phase I/II
Trial Sponsor: Dana-Farber Cancer Institute
Therapies Used in This Trial: Stereotactic body radiotherapy (SBRT), AGuIX